AR108102A1 - Compuestos agonistas de gpr119 y método para tratar enfermedades y afecciones mediado a través de gpr119 - Google Patents

Compuestos agonistas de gpr119 y método para tratar enfermedades y afecciones mediado a través de gpr119

Info

Publication number
AR108102A1
AR108102A1 ARP170100902A ARP170100902A AR108102A1 AR 108102 A1 AR108102 A1 AR 108102A1 AR P170100902 A ARP170100902 A AR P170100902A AR P170100902 A ARP170100902 A AR P170100902A AR 108102 A1 AR108102 A1 AR 108102A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
gpr119
affections
independently selected
Prior art date
Application number
ARP170100902A
Other languages
English (en)
Inventor
Anil Kumar
Santosh Kumar Rai
Himanshu Rai
Amol Pandurang Gunjal
Puneet Kumar
Jeevan Verma
Rakesh Ishwar Patil
Original Assignee
Mankind Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mankind Pharma Ltd filed Critical Mankind Pharma Ltd
Publication of AR108102A1 publication Critical patent/AR108102A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Compuestos derivados de 1,3,4-tiadizol, proceso para la preparación de los mismos y composición que comprende estos compuestos. Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1), en donde, X¹, X², X³, X⁴ y X⁵ son cada uno independientemente N, O, S o CH; y X⁴ y X⁵ se pueden combinar opcionalmente para formar un anillo de cinco miembros que comprende uno o más heteroátomos cada uno seleccionado independientemente a partir de N, O y S y el anillo adicional de cinco miembros puede estar además sustituido opcionalmente con uno o más del grupo seleccionado a partir de F, Cl, Br, I, CF₃ y C₁₋₆ alquilo; R¹ y R² se selecciona independientemente del grupo que comprende -H, -O, C₁₋₆ alquilo, C₁₋₆ alcoxi, -(CH₂)ₙ, amino, -CO, -CONH, -NH(alquilo), -N(alquilo)₂, -NH-aralquilo, -CH₂O, -OCH(CH₃), halógeno, COOR³, -CONR³R⁴, NR³COR⁴; R³ y R⁴ se selecciona independientemente del grupo que comprende hidrógeno o C₁₋₆ alquilo de cadena lineal o de cadena ramificada que puede estar adicionalmente sustituido con halógeno o C₁₋₆ alquilo; n es 0, 1, 2 ó 3; A se selecciona a partir de los restos del grupo de fórmulas (2); B se selecciona a partir de los restos del grupo de fórmulas (3); y sales, hidratos y estereoisómeros farmacéuticamente aceptables de los mismos.
ARP170100902A 2016-04-08 2017-04-07 Compuestos agonistas de gpr119 y método para tratar enfermedades y afecciones mediado a través de gpr119 AR108102A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201611012426 2016-04-08

Publications (1)

Publication Number Publication Date
AR108102A1 true AR108102A1 (es) 2018-07-18

Family

ID=58772935

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100902A AR108102A1 (es) 2016-04-08 2017-04-07 Compuestos agonistas de gpr119 y método para tratar enfermedades y afecciones mediado a través de gpr119

Country Status (14)

Country Link
US (2) US10208030B2 (es)
EP (1) EP3440078B1 (es)
JP (1) JP6810242B2 (es)
CN (1) CN109415359B (es)
AR (1) AR108102A1 (es)
AU (2) AU2017247691B2 (es)
CA (1) CA3020381C (es)
ES (1) ES2929880T3 (es)
MX (1) MX2018012085A (es)
NZ (2) NZ763528A (es)
RU (1) RU2734500C2 (es)
TW (2) TWI678367B (es)
WO (1) WO2017175066A1 (es)
ZA (1) ZA201807351B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10208030B2 (en) * 2016-04-08 2019-02-19 Mankind Pharma Ltd. GPR119 agonist compounds
US10954229B2 (en) * 2016-04-08 2021-03-23 Mankind Pharma Ltd. GPR119 agonist compounds
WO2017184520A1 (en) * 2016-04-18 2017-10-26 Vanderbilt University Substituted and fused 6-membered protease activated receptor 4 (par-4) antagonists
CN107879969B (zh) * 2017-12-26 2021-02-19 山东诚汇双达药业有限公司 一种n-苄基-4-哌啶甲酸的合成方法
EP3996704A4 (en) 2019-07-08 2023-07-12 Mankind Pharma Ltd MULTIPLE THERAPY INCLUDING GPR119 AGONISTS AND DPP-4 INHIBITORS
KR20220086619A (ko) 2019-10-21 2022-06-23 노파르티스 아게 기생충 질환 치료용 화합물 및 조성물
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CN111517985B (zh) * 2020-05-20 2023-05-12 济南百润医药科技有限公司 4-[(1r)-1-氨基-2-羟基乙基]-3-氟-苯腈的制备方法
EP4172162A1 (en) 2020-06-26 2023-05-03 Kallyope, Inc. Ampk activators
CN111978209B (zh) * 2020-09-07 2023-05-30 成都美域高制药有限公司 一种磷酸特地唑胺中间体3-氟-4-溴苯胺的合成方法
CN117203211A (zh) * 2021-11-29 2023-12-08 中国海洋大学 咪唑并噻唑衍生物及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2252613A1 (en) * 2008-02-22 2010-11-24 Irm, Llc Compounds and compositions as modulators of gpr119 activity
DK2280704T3 (en) 2008-03-31 2015-06-29 Cymabay Therapeutics Inc Oxymethylenarylforbindelser and uses thereof
US20110160222A1 (en) 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
US8940716B2 (en) 2010-05-06 2015-01-27 Bristol-Myers Squibb Company Bicyclic heteroaryl compounds as GPR119 modulators
CN102432598A (zh) * 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 三环化合物、其制备方法及其在医药上的应用
UY33805A (es) 2010-12-17 2012-07-31 Boehringer Ingelheim Int ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?.
JP5703393B2 (ja) * 2011-01-21 2015-04-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病、肥満および関連障害の治療のためのｇｐｒ１１９モジュレーターとしての縮合ジヒドロフラン
CN102898400B (zh) * 2011-07-28 2015-04-29 北京韩美药品有限公司 Gpr119激动剂及其应用
MX365108B (es) 2012-06-12 2019-05-23 Chong Kun Dang Pharmaceutical Corp Derivados piperidina para agonista gpr119.
IN2013MU03577A (es) * 2013-11-14 2015-07-31 Cadila Healthcare Ltd
US10208030B2 (en) * 2016-04-08 2019-02-19 Mankind Pharma Ltd. GPR119 agonist compounds
US10526345B2 (en) * 2016-04-08 2020-01-07 Mankind Pharma Ltd. Compounds as GPR119 agonists

Also Published As

Publication number Publication date
NZ763528A (en) 2023-06-30
BR112018070664A2 (pt) 2019-02-05
AU2017247691A1 (en) 2018-11-01
JP6810242B2 (ja) 2021-01-06
WO2017175066A1 (en) 2017-10-12
AU2017247691B2 (en) 2020-02-27
CA3020381A1 (en) 2017-10-12
RU2734500C2 (ru) 2020-10-19
NZ746950A (en) 2020-04-24
MX2018012085A (es) 2019-03-06
US10752622B2 (en) 2020-08-25
TWI708773B (zh) 2020-11-01
CA3020381C (en) 2020-12-15
TWI678367B (zh) 2019-12-01
US20170291894A1 (en) 2017-10-12
AU2020203450B2 (en) 2021-07-01
AU2020203450A1 (en) 2020-06-11
JP2019516782A (ja) 2019-06-20
RU2018138047A3 (es) 2020-05-12
US10208030B2 (en) 2019-02-19
CN109415359B (zh) 2022-03-04
RU2018138047A (ru) 2020-05-12
ES2929880T3 (es) 2022-12-02
CN109415359A (zh) 2019-03-01
EP3440078B1 (en) 2022-09-28
TW201945361A (zh) 2019-12-01
US20190127363A1 (en) 2019-05-02
TW201741309A (zh) 2017-12-01
ZA201807351B (en) 2019-07-31
EP3440078A1 (en) 2019-02-13

Similar Documents

Publication Publication Date Title
AR108102A1 (es) Compuestos agonistas de gpr119 y método para tratar enfermedades y afecciones mediado a través de gpr119
AR108101A1 (es) Compuestos agonistas de gpr119 y método para tratar enfermedades y afecciones mediado a través de gpr119
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
ES2525566T3 (es) Nuevo derivado de hidroxamato, método para producirlo y composición farmacéutica que lo contiene
AR092270A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CL2020001919A1 (es) Inhibidores de endonucleasa cap-dependientes.
AR105820A1 (es) Análogos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5
PE20210667A1 (es) Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1
AR087102A1 (es) Derivados de bencilamina como inhibidores de la calicreina plasmatica
AR093759A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR095885A1 (es) Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2
AR088092A1 (es) Procesos para preparar inhibidores de quinasas atr utiles para el tratamiento del cancer
ES2659222T3 (es) 7-azabicíclicos sustituidos y su uso para moduladores de receptores de orexina
EA201171062A1 (ru) Алкиламидные соединения и их применение
AR103412A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
AR097866A1 (es) Derivados de 4-azaindol
AR117398A1 (es) Inhibidores de la señalización mediada por tirosina cinasa 2
AR083579A1 (es) Inhibidor de cetp de oxazodilinona sustituida con amina ciclica
AR092288A1 (es) Ligandos del receptor ep1
EA201690888A1 (ru) Новые гетероциклические соединения
CL2020002588A1 (es) Compuestos derivados de indol, composiciones que los contienen, útiles en el tratamiento de infestación por helmintos, preferentemente trematodos, en mamíferos. (divisional de solicitud n° 03258-2016)
BR112014001083B8 (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do composto
AR097963A1 (es) Antagonistas de receptor ep3 de prostaglandina
PE20140629A1 (es) Derivados de fenil-isoxazol y procedimiento para la preparacion de los mismos
AR101696A1 (es) Compuestos de azetidiniloxifenilpirrolidina

Legal Events

Date Code Title Description
FG Grant, registration